Table 6: The comparison of the prevalence of adverse effects (episodes per 100 samples) between both groups.

Adverse events (AEs)Prevalence of events (%) Between-group value
DSG*DRSP*

Nausea/vomiting8 (17.8)1 (2.2)NS
Dizziness1 (2.2)4 (8.9)NS
Amenorrhea3 (6.7)1 (2.2)NS
Spotting2 (4.4)2 (4.4)NS
Mastalgia1 (2.2) 0 (0)NS

 *DSG: desogestrel group and DRSP: drospirenone group.